Speaking on the above topic is Dr Chih-Liang Chin, Director and Site Lead, Imaging, MSD/ Translation Medicine Research Centre, Singapore. He will be presenting at Drug Discovery World Asia 2012, part of a series of conferences at 5th Annual BioPharma Asia Convention 2012.
Chih-Liang Chin, Ph.D. is Director and Site Lead Imaging, Translational Medicine Research Centre at Merck & Sharp Dohme, Singapore. In this role, Chih-Liang provides leadership and coordination for the development of translational imaging biomarker in nonhuman primate across various disease franchises. His team also supports the early stage experimental medicine imaging study in human. Dr. Chin joined Merck in 2011 after seven years at Abbott Laboratories as Senior Scientist and Head, Neuroscience / Immunoscience Imaging, Translational Sciences, Global Pharmaceutical Research & Development, where his team focused on developing biomarkers in rodent models of neurological and psychiatric diseases using multi-modality imaging. Dr. Chin has received his Ph.D. in Bioengineering from the University of Pennsylvania. He was also Research Fellow in at Brigham & Women’s Hospital, Harvard Medical School. Throughout his career, he has actively published and served as Reviewer for several scientific imaging journals. Dr. Chin is currently a member of International Society of Magnetic Resonance in Medicine (ISMRM) and American Society for Pharmacology and Experimental Therapeutics (ASPET).
Dr Chin will be speaking on the following topics:
Translation imaging for CNS drug discovery and development
1. Formulating operational strategies of biomarker research process to reduce costs in R&D
2. Optimizing biomarkers and pharmacodynamics indicators for drug response and toxicity during drug discovery process
3. Developing innovative approaches to validate biomarkers to accelerate approval of biomarkers in drug development process